Ssy Group Limited · HKEX:2005
Ssy — FY2021 Earnings Presentation
31 slides from Ssy's earnings presentation, Mar 29, 2022
Slide 1: 2021 Results Analysts Meeting
2021 RESULTS ANALYSTS MEETING Updated on 29 March 2022 Copyright Copyright © 2016 ® 2022 SSYSSYGroup Group Limited. Limited. All Allrights rightsreserved. reserved.
Slide 2: Disclaimer
Disclaimer The presentation is prepared by SSY Group Limited (the “Company”) and is solely for the purpose of corporate communication and general reference only. The presentation is not intended as an offer to sell, or to solicit an offer to buy or to form an basis of investment decision for any cla
Slide 3: Financial Highlights
Financial Highlights （HK$'000） 2021 2020 Change Revenue 5,356,763 4,260,898 25.7% Gross Profit 2,186,517 2,708,375 17.1% Gross Profit Margin 59.2% 63.6% (4.4%pt) EBITDA 1,383,325 1,077,222 28.4% EBITDA Margin 25.8% 25.3% 0.5%pt Net Profit 785,533 611,971 28.4% Net Profit Margin 14.7% 14.4% 0.3%pt Ea
Slide 4: Agenda
Agenda 1. Business Profile 2. Competitive Advantages 3. Shareholding Structure 4. Financial Highlights SSY Group Limited • 4
Slide 5: Business Profile
Business Profile SSY Group Limited • 5
Slide 6: Group Structure
Group Structure SSY Group Limited (Stock Code: 2005.HK) 100% Shijiazhuang No.4 I.V. infusion solution, Ampoule Pharmaceutical Co., Ltd. products, Oral preparations, etc. 41% (No.4 Pharma) 59% 75% 100% 74% Jiangsu Best New Hebei Hanlin Hebei Guolong Hebei Guangxiang Other Medical Material Biotechnolo
Slide 7: Sales Breakdown by Product (2021)
Sales Breakdown by Product (2021) Non-PVC soft bag infusion solution Upright soft bag infusion solution 4.3% 20.4% PP plastic bottle infusion solution 10.0% 14.2% Glass bottle infusion 3.3% solution 4.6% Ampoule injections 11.0% Bulk Pharmaceuticals 32.2% Medical materials Other products SSY Group L
Slide 8: Competitive Advantages
Competitive Advantages SSY Group Limited • 8
Slide 9: Competitive Advantages
Competitive Advantages Preparations, Bulk Pharmaceuticals, Medical Materials, Diversified and Coordinated Development Numerous Specifications, Complete Preparation Types, Wide Coverage I.V. Infusion Production Line Intelligent Manufacturing, Largest Production Capacity on Single Factory Basis in PRC
Slide 10: Diversified and Coordinated Development
Competitive Advantages Preparations, Bulk Pharmaceuticals, Medical Materials, Diversified and Coordinated Development 1 medical institute, 2 preparation, 2 bulk pharmaceutical and 1 medical material production plant, forming whole-industry-chain by preparation+bulk pharmaceutical+medical material 22
Slide 11: Pharmaceutical Research Institute
Competitive Advantages Diversified and Coordinated Development - Pharmaceutical Research Institute It covers an area of 85 acres and has advanced equipment such as high-efficiency/ultra-high- performance liquid chromatographs, gas chromatographs, Fourier infrared spectrometers, and the leading hard
Slide 12: I.V. Infusion Production Base
Competitive Advantages Diversified and Coordinated Development – I.V. Infusion production base Shijiazhuang No.4 Pharmaceutical Major products: Non-PVC Soft Bag IV, Upright Soft Bag IV, PP Plastic Bottle IV, PP Ampoule Injections, Glass Bottle IV SSY Group Limited • 12
Slide 13: Bulk Pharmaceuticals Production Base
Competitive Advantages Diversified and Coordinated Development – Bulk Pharmaceuticals Production Base Hebei Guangxiang Pharmaceutical Major products: Caffeine Theophylline , Aminophylline Series Metronidazole, Benzoyl Metronidazole Nifedipine, Xanthinol nicotinate Cangzhou Lingang Youyi Chemical Acq
Slide 14: Medical Materials Production Base
Competitive Advantages Diversified and Coordinated Development – Medical Materials Production Base Jiangsu Best New Medical Material Major production: Bioprocessing film series Multi-layer co-extrusion infusion films Rubber stopper series Gasket series SSY Group Limited • 14
Slide 15: Numerous Varieties, Complete Dosage Form, Wide Coverage
Competitive Advantages Numerous Varieties, Complete Dosage Form, Wide coverage Production Approvals: 341 Preparations Approvals: 245 245 25 43 28 163 28 6 Bulk Medical Under Passed Awarded Preparations Others Medical Consistency Centralized Pharmaceuticals Materials Insurance Evaluation Procurement
Slide 16: I.V. Infusion Packaging Types
Competitive Advantages Numerous Specifications, Complete Preparation types, Wide Coverage I.V. Infusion ◼ By packaging: Non-PVC Soft Bag, Upright Soft Bag, PP Plastic Bottle & Glass Bottle SSY Group Limited • 16
Slide 17: Ampoule Injections
Competitive Advantages Numerous Specifications, Complete Preparation types, Wide Coverage Ampoule Injections ◼ Betahistine Sales over RMB 100million, continuous rapid growth ◼ Ambroxol Hydrochloride, Doxofylline & Ropivacaine Hydrochloride Awarded the tender of National Centralized Medicines Procure
Slide 18: Solid Preparations
Competitive Advantages Numerous Specifications, Complete Preparation types, Wide Coverage Solid preparations ◼ Cefdinir Capsule and Prucalopride Succinate Tablet Awarded the tender of National Centralized Medicines Procurement ◼ Abidol Hydrochloride Capsule Broad-spectrum antiviral drug SSY Group Li
Slide 19: I.V. Production Capacity Expansion
Competitive Advantages I.V. Infusion Production Line Intelligent Manufacturing, Largest Production Capacity on Single Factory Basis in PRC I.V. Production Capacity Expansion No. 4 Pharma Year Increase / Year Increase / From 2018 % change 2019 % change Year 2021 Non-PVC Soft Bag 730M 20M/3% 750M - 75
Slide 20: Revenue by Product 2021 vs 2020
Competitive Advantages 2021 2020 Revenue Revenue % of IV Revenue % of IV (HK$'000) Revenue (HK$'000) Revenue Non-PVC Soft Bag IV 1,724,474 32.2% 1,283,277 30.1% Upright Soft Bag IV 587,821 11.0% 412,854 9.7% PP Plastic Bottle IV 764,057 14.2% 696,861 16.3% Glass Bottle IV 228,013 4.3% 244,003 5.8% A
Slide 21: I.V. Infusion 2021 Revenue by Packaging
Competitive Advantages I.V. Infusion Production Line Intelligent Manufacturing, Largest Production Capacity on Single Factory Basis in PRC I.V. Infusion – 2021 Revenue By Packaging Average Selling Revenue % of IV Price (ASP) GP% (HK$'000) Revenue (HK$) Non-PVC Soft Bag 1,724,474 52.2% 3.74 63.7% Upr
Slide 22: I.V. Infusion 2021 Revenue by Pharmaceutical Products
Competitive Advantages I.V. Infusion Production Line Intelligent Manufacturing, Largest Production Capacity on Single Factory Basis in PRC I.V. Infusion – 2021 Revenue By Pharmaceutical Average Selling Products Revenue % of IV Price (ASP) GP% (HK$'000) Revenue (HK$) Basic Infusions 2,068,038 62.6% 2
Slide 23: Numerous Prize Recognition
Competitive Advantages Numerous Prize Recognition ◼ Top 100 enterprises in China pharmaceutical industry ◼ Top 30 best industrial enterprises with China pharmaceutical research and development product line ◼ Top 20 best pioneer enterprises with pharmaceutical internationalize ◼ National technology m
Slide 24: Future Development Outlook: Year 2021
Competitive Advantages Future Development Outlook Year 2021 ◼ Type I new drug NP-01, the first innovative drug type of the Group, has entered into the research of Phase I clinical trial ◼ Obtained 20 national production approvals including 7 infusion products, 3 ampoules, 2 solid preparation, 2 powd
Slide 25: Future Development Outlook: Year 2022
Competitive Advantages Future Development Outlook Year 2022 ◼ Capitalizing on the radiation and driving effects of the Group Purchasing Organisation Programme, strive to increase market shares and expand the proportion of high value-added products ◼ Focus to increase the sales volume of major types
Slide 26: Future Development Outlook: Year 2022 Targets
Competitive Advantages Future Development Outlook Year 2022 ◼ Target annual volume of infusion products 1,500 million bottles (bags), representing an increase of approximately 10.5% ◼ Target annual production volumes of major bulk drug products caffeine and azithromycin reaching 7,000 tonnes and 450
Slide 27: Shareholding Structure
Shareholding Structure SSY Group Limited • 27
Slide 28: Shareholding Structure
Shareholding Structure Updated as at 29 March 2022 No. of issued shares 2,992,179,385 Sichuan Kelun China Pharmaceutical Others Pharmaceutical Co., Ltd. Co., Ltd. and Mr. Qu Jiguang 20.2% 35.9% 43.9% SSY Group Limited (Stock Code: 2005.HK) 100% 41% Shijiazhuang No.4 Pharmaceutical Co., Ltd. 59% 100%
Slide 29: Financial Highlights
Financial Highlights SSY Group Limited • 29
Slide 30: Financial Highlights
Financial Highlights Increase/ As at 31 Dec 2021 As at 31 Dec 2020 (Decrease) （HK$'000） Cash and cash equivalent 1,661,736 1,445,905 215,831 Bank borrowings 3,103,195 2,427,072 676,123 Net Asset Value 6,492,708 5,915,211 577,497 Net Gearing Ratio 18.9% 14.9% 4.0pt Current Ratio 2.04 2.01 0.03 Invent
Slide 31: Thank You!
THANK YOU! Company contacts Meng Guo (Executive Director) Henry Chow (Executive Director & CFO) Tel : 852-2688 0869 Email : mengguo@ssygroup.com.hk henrychow@ssygroup.com.hk SSY Group Limited • 31